Introduction
Coronavirus disease 2019 (COVID‐19), caused by a novel coronavirus
called severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), is
the most common global disease. The high-risk groups of this disease,
which has been declared a pandemic by the world health organization
(WHO) today, are still not fully determined. Immunosuppressed patients
are regarded as a high‐risk cohort. In this view, previous experience
with similar viruses, such as SARS-CoV and MERS-CoV, suggests that solid
organ transplantation (SOT) recipients would be prone to have increased
morbidity and mortality. Early published studies in liver
transplantation (LT) and SOT recipients with COVİD-19 reported a rate of
up to %20 [1], exceeding the rate of the general population
[2].
Initial symptoms of patients with COVİD-19 are various, and the
percentage of mild illness symptoms seen is about 80% [3]. Patients
with SARS-Cov-2 may be completely asymptomatic or progress with severe
disease. Comorbidities and advanced age are the most important risk
factors among LT recipients and the general population [1]. It is
estimated that COVID-19 will be more symptomatic and severe in LT
recipients due to immunosuppression treatments. Our study aims to
determine the frequency of asymptomatic or mild disease in the LT
recipients.